Gastrointestinal Cancers: mCRC (Issue 6) | Special Reports

Dr. Jennifer Wu on Proliferations and Mutations in Colorectal Cancer

February 12, 2016

Clinical Articles

Jennifer Wu, MD, discusses the issue of deficiencies in enzymes that fix mismatch repairs in colorectal cancer. Wu says targeting the cancer-specific enzymes which allow tumors to repair themselves could stop tumor growth in patients.

Patient Populations Provide Sequencing Clues in Chemorefractory CRC

February 11, 2016

Clinical Articles

To gain further insight into TAS-102 and regorafenib, Targeted Oncology spoke with Tanios Bekaii-Saab, MD, on how he utilizes currently available data to provide optimal care for patients with chemorefractory CRC.

Early Development of Regorafenib: Was the Correct Dose Selected?

February 11, 2016

Clinical Articles

A first-in-human phase I dose-escalation study followed by a small expansion cohort, both of which were conducted solely in Germany, set the stage for what would soon become the FDA-approved dose for regorafenib (Stivarga) of 160 mg/day.

Clinical Review: Regorafenib in Refractory mCRC

February 11, 2016

Clinical Articles

"While adverse events across both populations were broadly similar, some did occur more frequently in patients with longer exposure, an observation that is possibly related to the longer duration in this subgroup," said Axel Grothey, MD.

Optimizing Outcomes With Regorafenib in Metastatic CRC

February 11, 2016

Clinical Articles

Regorafenib offers a unique challenge in terms of AE management. AEs with regorafenib have been reported across several clinical trials, and more recently, a clinical case study demonstrated the utility of regorafenib in a "real world" scenario, adding further insight.

Case Study Suggests Regorafenib Remains Effective Beyond Progression for mCRC

February 09, 2016

Clinical Articles

Many patients with metastatic colorectal cancer (CRC) will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC

January 22, 2016

Clinical Articles

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).